



島根大学学術情報リポジトリ
S W A N
Shimane University Web Archives of kNowledge

Title

Controlling Nutritional Status (CONUT) as a prognostic immunonutritional biomarker for gastric cancer after curative gastrectomy: a propensity score-matched analysis

Author(s)

Noriyuki Hirahara, Yoshitsugu Tajima, Yusuke Fujii, Shunsuke Kaji, Yasunari Kawabata, Ryoji Hyakudomi, Tetsu Yamamoto & Takahito Taniura

Journal

Surgical Endoscopy volume 33, pages4143–4152(2019)

Published

05 March 2019

URL

<https://doi.org/10.1007/s00464-019-06723-z>

この論文は出版社版ではありません。

引用の際には出版社版をご確認のうえご利用ください。

This is a post-peer-review, pre-copyedit version of an article published in Surgical Endoscopy. The final authenticated version is available online at:

<https://doi.org/10.1007/s00464-019-06723-z>

Original Article

Title: Controlling Nutritional Status (CONUT) as a prognostic immunonutritional biomarker for gastric cancer after curative gastrectomy: A propensity score-matched analysis

Short title: CONUT as prognostic biomarker for gastric cancer

Authors: Noriyuki Hirahara, Yoshitsugu Tajima, Yusuke Fujii, Shunsuke Kaji, Yasunari Kawabata, Ryoji Hyakudomi, Tetsu Yamamoto, and Takahito Taniura

Institution: Department of Digestive and General Surgery, Shimane University Faculty of Medicine

Keyword: gastric cancer, CONUT, CEA, overall survival

Research Support: This study received no external sources of funding.

Conflicts of interest: none to disclose

Corresponding author:

Department of Digestive and General Surgery,
Shimane University Faculty of Medicine
89-1 Enya-cho, Izumo, Shimane 693-8501, Japan
Noriyuki Hirahara
Tel: +81-853-20-2232

Abstract

Background: In clinical practice, it is not unusual to treat oncologic patients whose tumor markers are within normal range, even with advanced cancer. The Controlling Nutritional Status (CONUT) score could provide a useful nutritional and immunological prognostic biomarker for cancer patients. In this study, we assessed the prognostic value of the CONUT score for patients with gastric cancer, including a subgroup analysis with stratification based on serum carcinoembryonic antigen (CEA) level.

Methods: We retrospectively reviewed the medical records of 368 consecutive patients who underwent curative laparoscopy-assisted gastrectomy. The prognostic value of the CONUT score was compared between patients with a low (≤ 2) and high (≥ 3) score, with propensity score-matching (PSM) used to control for biasing covariates (Depth of tumor, Lymph node metastasis, pathological TNM (pTNM) stage).

Results: Overall survival (OS) among all patients was independently predicted by the tumor stage (hazard ratio (HR): 2.231, $p = 0.001$), the CONUT score (HR: 2.254, $p = 0.001$), and serum CEA level (HR: 1.821, $p = 0.025$). Among patients with a normal pre-operative serum CEA level, tumor stage (HR: 2.350, $p = 0.007$), and the CONUT score (HR: 1.990, $p = 0.028$) were independent prognostic factors of OS. In the high serum CEA level group, tumor size (HR: 2.930, $p = 0.015$) and the CONUT score (HR: 3.707, $p = 0.004$) were independent prognostic factors of OS.

Conclusions: It is advantageous to use both CEA level and the CONUT score to assess the prognosis of patients with gastric cancer, which reflect both tumor-related factors and host-related factors, respectively.

Introduction

Gastrectomy is the mainstay curative treatment for gastric cancer, although surgical outcomes remain poor due to the aggressive biological behavior of these tumors [1]. To precisely individualize treatment, and thus, improve the survival of patients with gastric cancer, it would be useful to have a comprehensive set of perioperative biomarkers that are predictive of postoperative survival [2, 3]. Biological parameters for evaluating immunonutritional status or screening tools for predicting the prognosis of cancer patients, such as the Glasgow prognostic score, the nutritional index, and the geriatric nutritional risk index, are limited in their clinical application, with no consensus having been reached regarding their usefulness for patients with gastric cancer [4, 5].

The controlling nutritional status (CONUT) score is calculated using three parameters, the serum albumin concentration, total cholesterol concentration, and total peripheral lymphocyte count, which reflect host protein metabolism, lipid metabolism and immune function, respectively [6]. As the CONUT score reflects both nutritional and immune status, we hypothesized that this score could be a useful nutritional and immunological biomarker to predict prognosis among cancer patients, allowing for effective customization of treatment, based on an individual's host-related factors, to improve long-term survival. The clinical significance of establishing an independent, and yet complementary prognostic biomarker other than conventional tumor markers is emphasized by the findings that carcinoembryonic antigen (CEA), which is a useful tumor marker for several cancers, including gastric cancer [7-9], is not necessarily elevated in all patients with cancer, even in those with advanced cancer [10], making treatment challenging. Accordingly, the purpose of our study was to evaluate the prognostic and predictive value of the CONUT score, after curative gastrectomy, to

predict survival among patients with gastric cancer.

Materials and Methods

Patients

We retrospectively reviewed the medical records of 368 consecutive patients who underwent curative laparoscopy-assisted gastrectomy for histologically confirmed gastric adenocarcinoma, with R0 resection, at the Department of Digestive and General surgery, Shimane University Faculty of Medicine, between January 2010 and December 2016. The median follow-up period for survival analysis was 35.3 months (4.0 – 97.0 months). The pathological Tumor-Node-Metastasis (TNM) classification was determined based on the 7th edition of the American Joint Committee on Cancer TNM classification system [11]. Postoperative complications were evaluated using the Clavien-Dindo classification, and clinically relevant complications were defined as those with a grade ≥ 2 [12]. To reduce the biasing effect of different distributions of covariates between groups of patients with a low and high CONUT score, a propensity score-matched (PSM) analysis was performed for depth of tumor, lymph node metastasis, and pathological TNM (pTNM) stage.

Laparoscopy-assisted gastrectomy was performed in all patients, including lymph node dissection performed as per the Japanese Gastric Cancer Treatment Guidelines (Version 3) [13]. Adjuvant chemotherapy, using 5-fluorouracil-based regimens, was recommended to patients with a histologically advanced gastric cancer.

The requirement for informed consent was waived because of the retrospective nature of this cohort study. All procedures were approved by the Institutional Review Board (IRB) and were in accordance with the Helsinki Declaration of 1965 and later

versions (UMIN:000030472).

Perioperative management

We introduced a multidisciplinary management team, including surgeon, anesthesiologist, dental hygienist doctor, pharmacist, nutritionist, and rehabilitation technician. This team mainly managed dental cleaning, medication assistance, physical exercise and rehabilitation, and nutritional support. We provided preoperative enteral nutrition to optimize preoperative condition as possible, which aimed to decrease the incidence rate of postoperative complications

Postoperative outcome evaluation

Clinical findings and surgical outcomes were extracted from the medical records. The observation period was from the date of surgery until the date of death or loss to follow-up. Overall survival (OS) was calculated from the date of primary gastrectomy to the date of death from any cause or the date of the last follow-up.

Evaluation of preoperative nutritional indices

All laboratory data used for calculating the preoperative nutritional status was obtained within 1 week before surgery. The CONUT score was calculated according to three parameters (serum albumin concentration, total cholesterol concentration, and total lymphocyte count in peripheral blood), and was classified into four categories (normal, mild, moderate, and severe risk of malnutrition), as described in Table 1. A receiver operating characteristic curve of the preoperative CONUT score was generated from the outcomes of the multiple logistic regression analysis of OS. The area under the

curve (AUC) estimation method was used to determine the predictive value of the CONUT for OS. Patients were classified in the high CONUT score group (the malnourished group), and in the low CONUT score group (the well-nourished group).

Statistical analyses

The PSM analysis was performed using R statistical package (version 3.1.3; <http://www.r-project.org>). All statistical analyses were conducted using the JMP software for Windows (version 12; SAS Institute, Cary, NC, USA). Continuous variables were expressed as the mean±standard deviation when normally distributed, or as median and inter-quartile range for non-parametric data. The differences between groups were analyzed using Student's *t*-test for continuous variables with parametric distribution and Kruskal-Wallis test for non-parametric distributed variables. Frequencies were compared using the chi-squared test. OS was calculated using the Kaplan-Meier method, and between-group differences evaluated using the log-rank test.

Cox proportional hazard regression models were constructed to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Univariate analyses were performed to identify the variables associated with OS. Variables with a *p* value <0.05 on univariate analyses were entered into a multivariate logistic regression analysis, with a *p* value <0.05 was considered statistically significant.

Results

Receiver operating curve of CONUT score for OS analysis and CONUT value according to the serum level of CEA.

The optimal cutoff score of the CONUT was set at 2, based on the 5-year

postoperative OS (sensitivity, 65.0%; specificity, 57.9%; and AUC, 0.625) (Fig. 1A).

No association between the CONUT score and the serum CEA level was detected using a one-way Kruskal-Wallis analysis ($p = 0.546$). The mean CONUT score for patients with a normal serum CEA level ($n = 157$) was 2.6 ± 2.2 , compared to 2.8 ± 2.3 for patients ($n = 53$) with a high serum CEA level (Fig. 1B).

Relationships between CONUT score and clinicopathological features

Based on the CONUT cutoff score ≤ 2 , 263 patients (71.5%) were classified into the well-nourished group, with 105 (28.5%) patients, having a CONUT score ≥ 3 , classified into the malnourished group. As shown in Table 2, the CONUT score was significantly associated with age ($p < 0.001$), white blood cell count (WBC; $p < 0.001$), tumor size ($p < 0.001$), operative procedure ($p = 0.041$), depth of tumor ($p < 0.001$), lymph node metastasis ($p = 0.005$), pTNM stage ($p < 0.001$), CRP level ($p < 0.001$), and postoperative complications ($p = 0.026$). PSM adequately balanced the distribution of confounding variables (depth of tumor, lymph node metastasis and pTNM stage) between the low and high CONUT score groups, with 105 matched pair identified, with a standardized or individualized follow-up, and used in subsequent analyses (Table 2).

Preoperative American Society of Anesthesiologists (ASA) physical status classification and preoperative comorbidities, such as hypertension, dyslipidemia, diabetes mellitus, respiratory functional disorder, history of the other organ cancers, cardiovascular disease, cerebrovascular disease, diabetes mellitus or liver dysfunction were not significantly associated with CONUT (data unshown).

Cox regression analysis of propensity score-matched cohort

Univariate analyses identified advanced pTNM stage ($p = 0.002$), high CONUT score ($p = 0.003$), high serum CEA level ($p = 0.027$), and operative procedure ($p = 0.007$) as being significantly associated with a worse OS. On the multivariate analysis, pTNM stage (hazard ratio (HR): 1.970, 95.0% CI: 1.199–3.235; $p = 0.007$), CONUT score (HR: 2.441, 95.0% CI: 1.463–4.071; $p < 0.001$), serum CEA level (HR: 1.832, 95.0% CI: 1.104–3.038; $p = 0.019$), and operative procedure (HR: 1.943, 95.0% CI: 1.165–3.239; $p = 0.011$) were confirmed as independent prognostic factors for OS among the PSM subgroup (Table 3).

OS analysis stratified by the CONUT score and the serum CEA level in the propensity score-matched cohort

In the PSM subset, Kaplan-Meier analysis and the log-rank test revealed a worse prognosis, in terms of OS, among patients with a high, compared to a low, CONUT score ($p < 0.001$). The 5-year OS rate for patients with a low and high CONUT score was 73.8% and 49.8%, respectively (Fig. 2A).

Also, in in the PSM subset, 53 patients with a high serum CEA level had a significantly lower OS, compared to the 157 patients with a normal CEA level ($p = 0.020$; Fig. 2B). The 5-year OS rate for patients with normal and high CEA levels were 67.5% and 45.4%, respectively.

Relationship between the CONUT score and the clinicopathological features of patients stratified by serum CEA level

Based on a CEA cutoff level of 5.0 ng/ml, 157 patients (74.8%) were included in the normal serum CEA group and 53 patients (25.2%) in the high CEA group. Among the

157 patients with a normal preoperative serum CEA level, 81 patients (51.6%) were classified in the low CONUT score group and the remaining 76 patients (48.4%) in the high CONUT score group, based on a CONUT cutoff score of 2. The CONUT score was significantly associated to age ($p = 0.006$), WBC ($p = 0.006$), tumor size ($p = 0.003$), and C-reactive protein (CRP) level ($p < 0.001$).

Among the 53 patients with a high preoperative serum CEA level, 24 (45.3%) were classified in the low CONUT score group (well-nourished) and the remaining 29 (54.7%) in the high CONUT score (malnourished), based on a CONUT cutoff score of 2. The CONUT score was significantly associated to age ($p = 0.015$), WBC ($p = 0.022$), CRP level ($p = 0.020$), postoperative complications ($p = 0.004$), and adjuvant chemotherapy ($p = 0.046$) (Table 4).

Cox regression analysis of OS among groups stratified for serum CEA level

On univariate analyses for patients with a normal serum CEA level, an advanced pTNM stage ($p = 0.008$), high CONUT score ($p = 0.032$), and operative procedure ($p = 0.038$) were significantly associated to a worse OS. On multivariate analysis, pTNM stage (HR: 2.065, 95% CI: 1.106–3.856; $p = 0.023$), CONUT score (HR: 2.240, 95% CI: 1.181–4.249; $p = 0.014$), and operative procedure (HR: 1.825, 95% CI: 0.951–4.249; $p = 0.071$) were independent prognostic factors of OS (data unshown).

On univariate analyses for patients with a high serum CEA level, a large tumor size ($p = 0.004$) and a high CONUT score ($p = 0.014$) were significantly associated to a worse OS. On multivariate analysis, tumor size (HR: 2.930, 95% CI: 1.228–7.655; $p = 0.015$) and the CONUT score (HR: 3.707, 95% CI: 1.500–10.607; $p = 0.004$) were independent prognostic factors of OS (data unshown).

OS analysis stratified by the CONUT score among groups stratified for serum CEA level

Among patients with a normal serum CEA level, the Kaplan-Meier analysis and log-rank test identified a significantly poorer OS among patients with a high CONUT score, compared to those with a low CONUT score ($p = 0.041$). The 5-year OS rate for patients with a low and high CONUT score was 76.2% and 58.6%, respectively.

Among patients with a high serum CEA level, a high CONUT score was associated to a significantly poorer OS than those with a low CONUT score ($p = 0.004$). The 5-year OS rate for patients with a low and high CONUT score was 67.9% and 28.3%, respectively (Fig. 3).

Discussion

There is good that cancer prognosis is not only related to tumor factors, but also patient status, including nutritional status and systemic inflammation [14, 15]. The clinical applicability of the CONUT score has been limited to the evaluation of nutritional status, although, recently, it has received greater attention as a predictive biomarker of survival among patients with different types of cancers [16, 17]. The CONUT score is calculated from the serum albumin concentration, total cholesterol concentration, and total lymphocyte count in peripheral blood, and, thus, reflects protein reserves, caloric depletion, and impaired immune defenses, respectively.

Cholesterol is an essential immunocomponent of cellular membranes. It has numerous biological functions, including membrane fluidity and membrane protein activity, which potentially correlate with the initiation and progression of cancer and the

immune response. Consequently, immunocompetent cells gain their capacity to exert an immunological response against the spread of tumor [18, 19]. Thus, hypocholesterolemia may contribute to a worse cancer prognosis. Lymphocytes play a fundamental role in the host's anticancer immune status by inducing apoptosis and by inhibiting cancer cell proliferation, invasion, and migration [20]. Therefore, lymphocytopenia may lead to tumor progression. Hypoalbuminemia reflects not only malnutrition or hyper-catabolism, but also systemic inflammation, which frequently induces a state of hypercytokinemia, resulting in an impaired immune response against cancer cells [21]. Therefore, the CONUT score reflects not only nutritional status but also the status of systemic inflammation and immune response [22]. In our retrospective study, we elucidated that patients with gastric cancer who had a high CONUT score (malnourished group) had a significantly poorer prognosis in terms of OS than those with a low CONUT score (well-nourished group). In addition, patients with a high CONUT score had a poorer tolerance to postoperative adjuvant chemotherapy than those with a low CONUT score ($p = 0.011$). Therefore, the poor tolerability of malnourished patients to anticancer treatment may explain the worse prognosis for OS in this group. These patients could possibly benefit from preoperative nutritional intervention and more intensive multimodal treatments.

Previous reports suggested that tumor-related factors, such as pTNM stage and CEA, were likely to be most reliable prognostic predictor for gastric cancer. Tumor markers play a significant role in the detection of tumors, treatment selection, the monitoring of the therapeutic response, and surveillance of various kinds of cancers. CEA is one of the most widely and frequently used tumor markers, especially for patients with gastrointestinal cancers [5, 6]. However, tumor markers, including CEA, are not always

reliable in establishing a definitive diagnosis and determining appropriate management of cancers as they lack the high sensitivity and specificity needed [23], even for advanced cancers. Therefore, in this study, we evaluated the utility of the CONUT as a potent predictive factor of survival, with a high CONUT score (indicative of malnourishment) being significantly associated to a worse OS, regardless of serum CEA level. In other word, the CONUT score was a significantly reliable and independent predictive biomarker of survival among patients treated for gastric cancer using gastrectomy. These findings support the widely accepted hypothesis that the overall survival of cancer patients is not only determined by tumor characteristics alone, but also associated by host-related inflammation and malnutrition [14, 15]. Given these findings, patients with gastric cancer who have a high CONUT score could benefit from a more intensive follow up, even after curative gastrectomy, with a preoperative nutritional intervention being of possible clinical benefit to improve the surgical outcomes in these patients.

On the other hand, The Nutritional Risk Index (NRI) was originally established by Bouillanne et al. for the screening index of the nutritional status of elderly hospitalized patients. NRI only requires measurements of height, weight, and serum albumin level [24]. Serum albumin may reflect chronic under-nutrition and deconditioning related to poor dietary habits. Malnutrition is one of the most common complicated disorder in gastrointestinal cancer patients. Therefore, biochemical markers, such as the albumin level, are the most commonly used markers of nutrition status. However, the relationship between the NRI and the morbidity of patients with gastrointestinal cancer has not yet been reported. Accordingly, the future study should to be evaluate the

predictive value of short and long-term outcomes of gastrointestinal cancer patients after laparoscopic curative gastrectomy.

Despite our important findings, there are a few limitations to the current study which need to be acknowledged. This study was a retrospective single-institution design using a relatively small sample size. Potential factors that can affect inflammation-based and nutritional markers, such as medications, cannot be excluded. In addition, other biomarkers such as rapid turnover proteins (transferrin, transthyretin, retinol-binding protein) were not adequately assessed. Therefore, future prospective randomized studies are warranted to investigate the significance of preoperative nutritional intervention for improving surgical outcome in gastric cancer patients.

Despite the above limitations, the CONUT is a convenient and useful biomarker to estimate nutritional status and for predicting OS among patients with gastric ulcer. Therefore, the CONUT score could be used as a complementary biomarker with the CEA level. In conclusion, the CONUT score is an objective, noninvasive, and readily available prognostic biomarker that has the potential to guide individualized treatment strategies to improve survival among patients with gastric cancer.

Acknowledgments: none

Compliance with ethical standards

Disclosures Drs. Noriyuki Hirahara, Yoshitsugu Tajima, Yusuke Fujii, Shunsuke Kaji, Tetsu Yamamoto, Ryoji Hyakudomi, Takahito Taniura, and Yasunari Kawabata have no conflicts of interest or financial ties to disclose.

References

1. Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global cancer incidence and mortality rates and trends-an update. *Cancer Epidemiol Biomarkers Prev.* 25:16–27. doi: 10.1158/1055-9965.
2. Niccolai E, Taddei A, Prisco D, Amedei A (2015) Gastric cancer and the epoch of immunotherapy approaches. *World J Gastroenterol.* 21;21(19):5778-93. doi: 10.3748/wjg.v21.i19.5778.
3. Hirahara N, Tajima Y, Fujii Y, Kaji S, Yamamoto T, Hyakudomi R, Taniura T, Kawabata Y (2018) Prognostic nutritional index as a predictor of survival in resectable gastric cancer patients with normal preoperative serum carcinoembryonic antigen levels: a propensity score matching analysis. *BMC Cancer.* 13;18(1):285. doi: 10.1186/s12885-018-4201-4.
4. Kurahara H, Maemura K, Mataka Y, Sakoda M, Iino S, Hiwatahi K, Kawasaki Y, Arigami T, Ishigami S, Kijima Y, Shinchi H, Takao S, Natsugoe S (2015) Prognostication by inflammation-based score in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. *Pancreatology.* 15(6):688-693. doi: 10.1016/j.pan.2015.09.015.
5. Kanemasa Y, Shimoyama T, Sasaki Y, Hishima T, Omuro Y (2018) Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma. *Ann Hematol.* 97(6):999-1007. doi: 10.1007/s00277-018-3273-1.
6. Ignacio de Ulibarri J, Gonzalez-Madrono A, de Villar NG, González P, González B, Mancha A, Rodríguez F, Fernández G (2005) CONUT: a tool for controlling nutritional status. First validation in a hospital population. *Nutr Hosp.* 20(1):38–45.

7. Kai Deng, Li Yang, Bing Hu, Hao Wu, Hong Zhu, Chengwei Tang (2015) The Prognostic Significance of Pretreatment Serum CEA Levels in Gastric Cancer: A Meta-Analysis Including 14651 Patients. *PLoS One*. 10(4): e0124151. Published online 2015 Apr 16. doi: 10.1371/journal.pone.012415.
8. Yingbo Shao, Xianfu Sun, Yaning He, Chaojun Liu, Hui Liu. (2015) Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer. *PLoS One*. 10(7): e0133830. Published online 2015 Jul 24. doi: 10.1371/journal.pone.0133830
9. Oscar Arrieta, David Saavedra-Perez, Roberto Kuri, Alejandro Aviles-Salas, Luis Martinez, Daniel Mendoza-Posada, Patricia Castillo, Alma Astorga, Enrique Guzman, Jaime De la Garza (2009) Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. *BMC Cancer*. 9: 119. Published online 2009 Apr 22. doi: 10.1186/1471-2407-9-119
10. Chen C, Chen Q, Zhao Q, Liu M, Guo J (2017) Value of Combined Detection of Serum CEA, CA72-4, CA19-9, CA15-3 and CA12-5 in the Diagnosis of Gastric Cancer. *Ann Clin Lab Sci*. 47(3):260–263.
11. Sobin L, Gospodarowicz M, Wittekind C, editors. International Union against Cancer (UICC). TNM classification of malignant tumors, 7th ed. New York: Wiley-Blackwell; 2010.
12. Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg*. 240(2):205-213.
13. Japanese Gastric Cancer Association Japanese gastric cancer treatment guidelines

- 2010 (ver.3) *Gastric Cancer*. 2011;14:113–123. doi: 10.1007/s10120-011-0042-4.
14. Ogino S, Galon J, Fuchs CS, Dranoff G (2011) Cancer immunology--analysis of host and tumor factors for personalized medicine. *Nat Rev Clin Oncol*. 9;8(12):711-719. doi: 10.1038/nrclinonc.2011.122.
15. Milsom C, Yu J, May L, Meehan B, Magnus N, Al-Nedawi K, Luyendyk J, Weitz J, Klement P, Broze G, Mackman N, Rak J (2007) The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression. *Thromb Res*. 120 Suppl 2:S82-91. Erratum in: *Thromb Res*. 2008;123(1):187-190.
16. Hirahara N, Matsubara T, Hayashi H, Takai K, Nakada S, Tajima Y (2018) Prognostic Importance of Controlling Nutritional Status in Patients Undergoing Curative Thoracoscopic Esophagectomy for Esophageal Cancer. *Am J Ther*. 25(5):e524-e532. doi: 10.1097/MJT.0000000000000414.
17. Akamine T, Toyokawa G, Matsubara T, Kozuma Y, Haratake N, Takamori S, Katsura M, Takada K, Shoji F, Okamoto T, Maehara Y (2017) Significance of the Preoperative CONUT Score in Predicting Postoperative Disease-free and Overall Survival in Patients with Lung Adenocarcinoma with Obstructive Lung cancer. *Anticancer Res*. 37(5):2735-2742.
18. Verstraeten SL, Albert M, Paquot A, Muccioli GG, Tyteca D, Mingeot-Leclercq MP (2018) Membrane cholesterol delays cellular apoptosis induced by ginsenoside Rh2, a steroid saponin. *Toxicol Appl Pharmacol*. 18;352:59-67. doi: 10.1016/j.taap.2018.05.014
19. Zhang G, Zhang D, Wu J, Zhang F, Zhu Z, Chen K, Zhang N, Jin J, Feng J, Lin N, Zhang Y, Yu H, Su D, Ying L (2018) Low Serum Levels of Pre-Surgical Total Cholesterol are Associated with Unfavorable Overall Survival in Patients with



- Operable Non-Small Cell Lung Cancer. *Clin Lab*. 64(3):321-327. doi:
10.7754/Clin.Lab.2017.170823
20. Lim JA, Oh CS, Yoon TG, Lee JY, Lee SH, Yoo YB, Yang JH, Kim SH (2018)
The effect of propofol and sevoflurane on cancer cell, natural killer cell, and
cytotoxic T lymphocyte function in patients undergoing breast cancer surgery: an in
vitro analysis. *BMC Cancer*. 7;18(1):159. doi: 10.1186/s12885-018-4064-8
21. Lucijanic M, Veletic I, Rahelic D, Pejisa V, Cicic D, Skelin M, Livun A, Tupek
KM, Stoos-Veic T, Lucijanic T, Maglicic A, Kusec R (2018) Assessing
serum albumin concentration, lymphocyte count and prognostic nutritional index
might improve prognostication in patients with myelofibrosis. *Wien Klin
Wochenschr*. 130(3-4):126-133. doi: 10.1007/s00508-018-1318-z
22. Alcorta MD, Alvarez PC, Cabetas RN, Martín MA, Valero M, Candela CG
(2018) The importance of serum albumin determination method to classify patients
based on nutritional status. *Clin Nutr ESPEN*. 25:110-113. doi:
10.1016/j.clnesp.2018.03.124
23. Christou N, Perraud A, Blondy S, Jauberteau MO, Battu S, Mathonnet M (2017)
The extracellular domain of E cadherin linked to invasiveness in colorectal cancer: a
new resistance and relapses monitoring serum-bio marker? *J Cancer Res Clin
Oncol*. 143(7):1177-1190. doi: 10.1007/s00432-017-2382-x
24. Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I,
Benazeth S, Cynober L, Aussel C (2005) Geriatric Nutritional Risk Index: a new
index for evaluating at-risk elderly medical patients. *Am J Clin Nutr* 82:777–783



Figure Legends


Fig. 1 A Receiver operating curve for post-operative survival was plotted to verify the optimum cutoff value of CONUT score for OS. B CONUT values in propensity score-matched 210 gastric cancer patients according to the serum level of CEA. Kruskal-Wallis test: $p = 0.546$. Each box represents interquartile ranges with median as horizontal line. Vertical bars indicate the maximum to minimum range.

Fig. 2A Postoperative OS based on CONUT score in propensity score-matched 210 gastric cancer patients. B Postoperative OS based on serum CEA level in 210 gastric cancer patients.

Fig. 3A Postoperative OS based on CONUT score in 157 gastric cancer patients with normal serum CEA level. B Postoperative OS based on CONUT score in 53 gastric cancer patients with high serum CEA level.







No. at risk

| | 0 | 12 | 24 | 36 | 48 | 60 | 72 | 84 | 96 |
|---------------------------------|----|----|----|----|----|----|----|----|----|
| CONUT ≤ 2 & CEA < 5.0 | 81 | 69 | 53 | 37 | 25 | 16 | 8 | 5 | 1 |
| CONUT ≥ 3 & CEA < 5.0 | 76 | 58 | 44 | 32 | 22 | 13 | 6 | 3 | 2 |
| CONUT ≤ 2 & CEA ≥ 5.0 | 24 | 23 | 19 | 12 | 10 | 9 | 4 | 2 | 1 |
| CONUT ≥ 3 & CEA ≥ 5.0 | 29 | 21 | 15 | 11 | 5 | 3 | 1 | 1 | 1 |

Table 1. Controlling Nutritional Status index score: assessment of malnutritional state

| Parameter | malnutritional state | | | |
|--------------------------------|----------------------|-------------|-------------|--------|
| | Normal | Mild | Moderate | Severe |
| Albumin (g/dl) | ≥ 3.50 | 3.00 - 3.49 | 2.50 - 2.99 | < 2.50 |
| Score | 0 | 2 | 4 | 6 |
| Total lymphocyte count (mg/ml) | ≥ 1600 | 1200 - 1599 | 800 - 1199 | < 800 |
| Score | 0 | 1 | 2 | 3 |
| Total cholesterol (mg/dl) | ≥ 180 | 140 - 179 | 100 - 139 | < 100 |
| Score | 0 | 1 | 2 | 3 |
| Total score | 0 - 1 | 2 - 4 | 5 - 8 | 9 - 12 |

Table 2. Relationships between CONUT score and clinicopathological features before and after propensity score matching

| Characteristics | Total patients | All patients | | | Total patients | Propensity matched patients | | |
|-----------------------|----------------|-------------------|------------------|----------------|----------------|-----------------------------|------------------|----------------|
| | | CONUT | | <i>p</i> value | | CONUT | | <i>p</i> value |
| | | ≤ 2 (n = 263) | ≥ 3 (n = 105) | | | ≤ 2 (n = 105) | ≥ 3 (n = 105) | |
| Age (years) | | 69 (36-89) | 77 (43-91) | <0.001 | | 70 (36-89) | 77 (43-91) | <0.001 |
| Gender | | | | 0.537 | | | | 0.537 |
| Male | 254 | 184 (70.0%) | 70 (66.7%) | | 146 | 76 (72.4%) | 70 (66.7%) | |
| Female | 114 | 79 (30.0%) | 35 (33.3%) | | 64 | 29 (27.6%) | 35 (33.3%) | |
| BMI | | 22.4 (15.4-31.6) | 22.0 (13.9-32.8) | 0.084 | | 22.2 (15.4-30.1) | 22.0 (13.9-32.8) | 0.296 |
| WBC | | 5800 (3160-10300) | 5070 (510-9750) | <0.001 | | 5920 (3160-10300) | 5070 (510-9750) | <0.001 |
| Location of tumor | | | | 0.198 | | | | 0.372 |
| EGJ | 11 | 7 (2.7%) | 4 (3.8%) | | 8 | 4 (3.8%) | 4 (3.8%) | |
| U | 70 | 47 (17.9%) | 23 (21.9%) | | 46 | 23 (21.9%) | 23 (21.9%) | |
| M | 162 | 125 (47.5%) | 37 (35.2%) | | 85 | 48 (45.7%) | 37 (35.2%) | |
| L | 125 | 84 (31.9%) | 41 (39.0%) | | 71 | 30 (28.6%) | 41 (39.0%) | |
| Tumor size (mm) | | 36 (3-180) | 55 (5-170) | <0.001 | | 40 (4-180) | 55 (5-170) | 0.002 |
| Procedure | | | | 0.041 | | | | 0.436 |
| LTG | 82 | 51 (19.4%) | 31 (29.5%) | | 62 | 31 (29.5%) | 31 (29.5%) | |
| LPG | 37 | 31 (11.8%) | 6 (5.7%) | | 17 | 11 (10.5%) | 6 (5.7%) | |
| L(A)DG | 249 | 181 (68.8%) | 68 (64.8%) | | 131 | 63 (60.0%) | 68 (64.8%) | |
| Differentiation | | | | 0.576 | | | | 0.728 |
| Well | 71 | 54 (20.5%) | 17 (16.2%) | | 30 | 13 (12.4%) | 17 (16.2%) | |
| Moderate | 134 | 96 (36.5%) | 38 (36.2%) | | 77 | 39 (37.1%) | 38 (36.2%) | |
| Poor | 163 | 113 (43.0%) | 50 (47.6%) | | 103 | 53 (50.5%) | 50 (47.6%) | |
| Depth of tumor | | | | <0.001 | | | | 1.000 |
| T1a-1b | 192 | 158 (60.1%) | 34 (32.4%) | | 68 | 34 (32.4%) | 34 (32.4%) | |
| 2 | 48 | 31 (11.8%) | 17 (16.2%) | | 34 | 17 (16.2%) | 17 (16.2%) | |
| 3 | 54 | 32 (12.2%) | 22 (21.0%) | | 44 | 22 (21.0%) | 22 (21.0%) | |
| 4a-4b | 74 | 42 (16.0%) | 32 (30.5%) | | 64 | 32 (30.5%) | 32 (30.5%) | |
| Lymph node metastasis | | | | 0.005 | | | | 0.996 |
| N0 | 244 | 189 (71.9%) | 55 (52.4%) | | 110 | 55 (52.4%) | 55 (52.4%) | |
| N1 | 40 | 23 (8.7%) | 17 (16.2%) | | 35 | 18 (17.1%) | 17 (16.2%) | |
| N2 | 42 | 25 (9.5%) | 17 (16.2%) | | 34 | 17 (16.2%) | 17 (16.2%) | |
| N3 | 42 | 26 (9.9%) | 16 (15.2%) | | 31 | 15 (14.3%) | 16 (15.2%) | |
| p TNM stage | | | | <0.001 | | | | 0.986 |

| | | | | | | | | |
|------------------------------|-----|-------------------|------------------|--------|-----|-------------------|------------------|--------|
| 1a-1b | 217 | 175 (66.5%) | 42 (40.0%) | | 83 | 41 (39.0%) | 42 (40.0%) | |
| 2a-2b | 65 | 36 (13.7%) | 29 (27.6%) | | 59 | 30 (28.6%) | 29 (27.6%) | |
| 3a-3c | 86 | 52 (19.8%) | 34 (32.4%) | | 68 | 34 (32.4%) | 34 (32.4%) | |
| Operation time (min) | | 398 (218-836) | 399 (177-911) | 0.390 | | 403 (218-836) | 399 (177-911) | 0.201 |
| Intraoperative bleeding (ml) | | 50 (0-3600) | 100 (0-5850) | 0.059 | | 85 (0-3600) | 100 (0-5850) | 0.846 |
| CEA antigen (ng/ml) | | 3.2 (0.7-161.1) | 3.4 (0.8-163.3) | 0.207 | | 3.4 (0.7-84.7) | 3.4 (0.8-163.3) | 0.666 |
| CRP (mg/l) | | 0.06 (0.002-7.09) | 0.24 (0.01-6.25) | <0.001 | | 0.08 (0.002-7.09) | 0.24 (0.01-6.25) | <0.001 |
| Postoperative complications | | | | 0.026 | | | | 0.242 |
| Present | 106 | 67 (25.5%) | 39 (37.1%) | | 70 | 31 (29.5%) | 39 (37.1%) | |
| Absent | 262 | 196 (74.5%) | 66 (62.9%) | | 140 | 74 (70.5%) | 66 (62.9%) | |
| Adjuvant chemotherapy | | | | 0.368 | | | | 0.011 |
| Yes | 100 | 68 (25.9%) | 32 (30.5%) | | 82 | 50 (47.6%) | 32 (30.5%) | |
| No | 268 | 195 (74.1%) | 73 (69.5%) | | 128 | 55 (52.4%) | 73 (69.5%) | |

CONUT controlling nutritional status, CEA carcinoembryonic antigen, BMI body mass index, WBC white blood cell, EGJ esophagogastric junction, U upper, M middle, L lower, LTG laparoscopic total gastrectomy, LPG laparoscopic proximal gastrectomy, L(A)DG laparoscopic (assisted) distal gastrectomy, pTNM stage pathological TNM stage, CRP C-reactive protein

Table 3. Univariate and multivariate analyses to assess the prognostic factors in propensity score-matched gastric cancer patients

| Variables | Category or characteristics | Patients (n = 210) | Univariate analysis | | | Multivariate analysis | | |
|-----------------------------|-----------------------------|--------------------|---------------------|---------------|----------------|-----------------------|---------------|----------------|
| | | | HR | 95% CI | <i>p</i> value | HR | 95% CI | <i>p</i> value |
| Gender | (female / male) | 64 / 146 | 1.282 | 0.764 - 2.240 | 0.355 | | | |
| Age | (< 70 / ≥ 70) | 84 / 126 | 1.416 | 0.852 - 2.428 | 0.183 | | | |
| BMI | (≥ 18.5 / < 18.5) | 185 / 25 | 1.226 | 0.566 - 2.355 | 0.580 | | | |
| Tumor size | (< 50mm / ≥ 50mm) | 105 / 105 | 1.622 | 0.993 - 2.704 | 0.053 | | | |
| Differentiation | (well & mod / poor) | 107 / 103 | 1.559 | 0.956 - 2.578 | 0.075 | | | |
| pTNM Stage | (1,2 / 3) | 142 / 68 | 2.152 | 1.323 - 3.493 | 0.002 | 1.970 | 1.199 - 3.235 | 0.007 |
| CONUT | (≤ 2 / ≥ 3) | 105 / 105 | 2.139 | 1.304- 3.589 | 0.003 | 2.441 | 1.463 - 4.071 | < 0.001 |
| CEA | (< 5.0 / ≥ 5.0) | 157 / 53 | 1.802 | 1.074- 2.960 | 0.027 | 1.832 | 1.104 - 3.038 | 0.019 |
| CRP | (< 0.5 / ≥ 0.5) | 165 / 45 | 1.479 | 0.846 - 2.481 | 0.164 | | | |
| Operative procedure | (PG & DG/TG) | 148 / 62 | 1.973 | 1.207 - 3.224 | 0.007 | 1.943 | 1.165 - 3.239 | 0.011 |
| Postoperative complications | (absent / present) | 140 / 70 | 1.483 | 0.887 - 2.428 | 0.130 | | | |
| Adjuvant chemotherapy | (no / yes) | 128 / 82 | 0.787 | 0.472 - 1.286 | 0.342 | | | |

BMI body mass index, CONUT controlling nutritional status, CEA carcinoembryonic antigen, CRP C-reactive protein,
PG laparoscopic proximal gastrectomy, DG laparoscopic (assisted) distal gastrectomy, TG laparoscopic total gastrectomy

Table 4. Relationships between CONUT score and clinicopathological features in serum CEA level stratified gastric cancer patients.

| Characteristics | Total patients | Normal serum CEA | | | Total patients | Elevated serum CEA | | |
|-----------------------|----------------|------------------|------------------|----------------|----------------|--------------------|------------------|----------------|
| | | CONUT | | <i>p</i> value | | CONUT | | <i>p</i> value |
| | | ≤ 2 (n = 81) | ≥ 3 (n = 76) | | | ≤ 2 (n = 24) | ≥ 3 (n = 29) | |
| Age (years) | | 70 (36-89) | 77 (43-91) | 0.006 | | 69 (54-87) | 79 (56-88) | 0.015 |
| Gender | | | | 0.785 | | | | 0.143 |
| Male | 107 | 56 (69.1%) | 51 (67.1%) | | 39 | 20 (83.3%) | 19 (65.5%) | |
| Female | 50 | 25 (30.9%) | 25 (32.9%) | | 14 | 4 (16.7%) | 10 (34.5%) | |
| BMI | | 22.2 (15.4-29.8) | 21.9 (13.9-32.8) | 0.563 | | 22.3 (18.8-30.1) | 22.1 (14.9-30.7) | 0.288 |
| WBC | | 5910 (3160-9830) | 5135 (510-8110) | 0.006 | | 6100 (3830-10300) | 5060 (3080-9750) | 0.022 |
| Location of tumor | | | | 0.680 | | | | 0.081 |
| EGJ | 8 | 4 (4.9%) | 4 (5.3%) | | 0 | 0 (0%) | 0 (0%) | |
| U | 31 | 18 (22.2%) | 13 (17.15) | | 15 | 5 (20.8%) | 10 (34.5%) | |
| M | 67 | 36 (44.4%) | 31 (40.8%) | | 18 | 12 (50.0%) | 6 (20.7%) | |
| L | 51 | 23 (28.4%) | 28 (36.8%) | | 20 | 7 (29.2%) | 13 (44.8%) | |
| Tumor size (mm) | | 40 (4-180) | 55 (8-150) | 0.003 | | 48 (12-140) | 54 (5-170) | 0.275 |
| Procedure | | | | 0.318 | | | | 0.797 |
| LTG | 44 | 24 (29.6%) | 20 (26.3%) | | 18 | 7 (29.2%) | 11 (37.9%) | |
| LPG | 13 | 9 (11.1%) | 4 (5.3%) | | 4 | 2 (8.3%) | 2 (6.9%) | |
| L(A)DG | 100 | 48 (59.3%) | 52 (68.4%) | | 31 | 15 (62.5%) | 16 (55.2%) | |
| Differentiation | | | | 0.314 | | | | 0.435 |
| Well | 21 | 8 (9.9%) | 13 (17.1%) | | 9 | 5 (20.8%) | 4 (13.8%) | |
| Moderate | 58 | 29 (35.8%) | 29 (38.2%) | | 19 | 10 (41.7%) | 9 (31.0%) | |
| Poor | 78 | 44 (54.3%) | 34 (44.7%) | | 25 | 9 (37.5%) | 16 (55.2%) | |
| Depth of tumor | | | | 0.973 | | | | 0.894 |
| T1a-1b | 54 | 28 (34.6%) | 26 (34.2%) | | 14 | 6 (25.0%) | 8 (27.6%) | |
| 2 | 24 | 13 (16.0%) | 11 (14.5%) | | 10 | 4 (16.7%) | 6 (20.7%) | |
| 3 | 32 | 17 (21.0%) | 15 (19.7%) | | 12 | 5 (20.8%) | 7 (24.1%) | |
| 4a-4b | 47 | 23 (28.4%) | 24 (31.6%) | | 17 | 9 (37.5%) | 8 (27.6%) | |
| Lymph node metastasis | | | | 0.906 | | | | 0.784 |
| N0 | 87 | 44 (54.3%) | 43 (56.6%) | | 23 | 11 (45.8%) | 12 (41.4%) | |
| N1 | 26 | 15 (18.5%) | 11 (14.5%) | | 9 | 3 (12.5%) | 6 (20.7%) | |
| N2 | 23 | 11 (13.6%) | 12 (15.8%) | | 10 | 6 (25.0%) | 5 (17.2%) | |
| N3 | 21 | 11 (13.6%) | 10 (13.2%) | | 31 | 4 (16.7%) | 6 (20.7%) | |
| p TNM stage | | | | 0.996 | | | | 0.878 |
| 1a-1b | 66 | 34(42.0%) | 32 (42.1%) | | 17 | 7 (29.2%) | 10 (34.5%) | |

| | | | | | | | | |
|------------------------------|-----|-------------------|------------------|--------|----|------------------|------------------|-------|
| 2a-2b | 43 | 22 (27.2%) | 21 (27.6%) | | 16 | 8 (33.3%) | 8 (27.6%) | |
| 3a-3c | 48 | 25 (30.9%) | 23 (30.3%) | | 20 | 9 (37.5%) | 11 (37.9%) | |
| Operation time (min) | | 398 (218-836) | 404 (177-911) | 0.2623 | | 440.5 (293-729) | 399 (249-881) | 0.497 |
| Intraoperative bleeding (ml) | | 80 (0-3600) | 50 (0-1960) | 0.665 | | 115 (0-2230) | 220 (0-5850) | 0.407 |
| CRP (mg/l) | | 0.08 (0.002-7.09) | 0.24 (0.01-6.25) | <0.001 | | 0.07 (0.01-5.35) | 0.24 (0.01-3.16) | 0.020 |
| Postoperative complications | | | | 0.825 | | | | 0.004 |
| Present | 53 | 28 (34.6%) | 25 (32.9%) | | 17 | 3 (12.5%) | 14 (48.3%) | |
| Absent | 104 | 53 (65.4%) | 51 (67.1%) | | 36 | 21 (87.5%) | 15 (51.7%) | |
| Adjuvant chemotherapy | | | | 0.067 | | | | 0.046 |
| Yes | 59 | 36 (44.4%) | 23 (30.3%) | | 23 | 14 (58.3%) | 9 (31.0%) | |
| No | 98 | 45 (55.6%) | 53 (69.7%) | | 30 | 10 (41.7%) | 20 (69.0%) | |

CONUT controlling nutritional status, CEA carcinoembryonic antigen, BMI body mass index, WBC white blood cell, EGJ esophagogastric junction, U upper, M middle, L lower, LTG laparoscopic total gastrectomy, LPG laparoscopic proximal gastrectomy, L(A)DG laparoscopic (assisted) distal gastrectomy, pTNM stage pathological TNM stage, CRP C-reactive protein

